85,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

Incidences of inflammatory airway diseases are on the rise across the world and it is imperative that research be undertaken to discover new treatment options. This volume discusses clinically successful and potential lipid targets that can make a difference in treating some of the most intractable disease states. Topics include the role of enzymes in lipid mediator synthesis; the biology of arachidonic acid, platelet-activating factor, and lysophosphatidic acid; and proresolution lipid mediators in inflammatory airway disease conditions. The book also examines the role of sphingosine and…mehr

Produktbeschreibung
Incidences of inflammatory airway diseases are on the rise across the world and it is imperative that research be undertaken to discover new treatment options. This volume discusses clinically successful and potential lipid targets that can make a difference in treating some of the most intractable disease states. Topics include the role of enzymes in lipid mediator synthesis; the biology of arachidonic acid, platelet-activating factor, and lysophosphatidic acid; and proresolution lipid mediators in inflammatory airway disease conditions. The book also examines the role of sphingosine and ceramide in inflammatory airway disease, and protein kinases activated by lipid mediators.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Abhijit Ray has worked in human trials with molecules designed to treat airway inflammation associated with asthma and COPD and has published more than 60 articles in peer-reviewed journals. He has been the senior director and head of biology research at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. As a member of the drug discovery team, he manages a group of 60 scientists engaged in discovery research for drugs in the areas of infectious and inflammatory diseases. Punit Srivastava has been a group leader of biology at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. He was a member of the drug discovery group of Ranbaxy Laboratories Ltd. from 2004 to June 2010 and has worked for more than six years in drug discovery research, which has resulted in one molecule entering human trial for COPD. He has published more than 15 articles in peer-reviewed journals and filed at least six patents. As a member of the drug discovery team at Daiichi Sankyo, he is leading projects in the area of inflammation.